Inhibikase Therapeutics financials
$2.02−1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $260.5K | $123.4K | $3.1M | $698.5K |
| Gross profit | $0.00 | $0.00 | $260.5K | $123.4K | $3.1M | $698.5K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M | -$2.8M |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M | -$2.8M |
| Net margin | — | — | −7304.7% | −14625.9% | −476.9% | −407.7% |
| Diluted EPS | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-4.86 | $-2.10 |
| EBITDA | -$51.9M | -$28.6M | -$19.9M | -$18.1M | -$14.8M | -$2.8M |
| Operating cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M | -$1.1M |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | -$14.3M | — |
| Diluted shares | 98.3M | 23.7M | 6.0M | 4.2M | 3.0M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $139.2M | $56.5M | $9.2M | $7.2M | $40.8M | $14.0M |
| Short-term investments | $39.5M | $41.1M | $4.1M | $15.9M | $0.00 | — |
| Total debt | $0.00 | $110.5K | $622.0K | $351.3K | $248.9K | $319.0K |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M | $5.0M |
| Shareholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology